發(fā)布時間：2018-05-23 21:04

  本文選題：臍帶 + 間質(zhì)干細胞移植　； 參考：《中國組織工程研究》2015年19期

【摘要】：背景:國內(nèi)外已有應(yīng)用間充質(zhì)干細胞治療肝硬化的臨床研究且取得了可喜的進步,但在實際應(yīng)用中,經(jīng)常會誤用t檢驗分析這類資料。目的:采用重復(fù)測量方法分析臍帶間充質(zhì)干細胞治療肝硬化患者的有效性和安全性。方法:失代償性肝硬化患者27例,均行常規(guī)內(nèi)科治療,包括護肝、對癥治療等。在入院1周后靜脈移植臍帶間充質(zhì)干細胞(第2-4代),細胞存活率≥90%,干細胞數(shù)量≥2×107個,共治療4次,每次間隔5-7 d。使用重復(fù)測量方差分析臍帶間充質(zhì)干細胞移植治療不同時點的肝功能變化。結(jié)果與結(jié)論:單變量重復(fù)測量方差分析結(jié)果顯示,在治療后2,3個月時血清白蛋白升高、總膽紅素降低,與治療前比較差異有顯著性意義(P0.05);治療后3個月,谷草轉(zhuǎn)氨酶降低、膽堿酯酶升高,與治療前比較差異有顯著性意義(P0.05),所有患者在觀察期內(nèi)無肝臟及其他器官腫瘤發(fā)生。結(jié)果表明臍帶間充質(zhì)干細胞移植治療肝硬化安全有效,患者肝功能得到改善。
[Abstract]:Background: mesenchymal stem cells (MSCs) have been used in the treatment of liver cirrhosis in China and abroad and have made gratifying progress. However, t test is often misused to analyze this kind of data in practical application. Objective: to analyze the efficacy and safety of umbilical cord mesenchymal stem cells in the treatment of patients with liver cirrhosis. Methods: 27 patients with decompensated cirrhosis were treated with routine medical treatment, including liver protection and symptomatic treatment. One week after admission, umbilical cord mesenchymal stem cells were transplanted via vein (2-4 passage, cell survival rate 鈮，

本文編號：1926385